Paolo Avanzini

Statistics

Publications

Citations

632

H-Index

Active since

1993

Affiliations

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico(Current)

Azienda ospedaliera "Bianchi-Melacrino-Morelli"

Sapienza University of Rome

Istituti di Ricovero e Cura a Carattere Scientifico

University of Siena

Paolo Avanzini is an author at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico specializing in medicine, oncology, and hematologic malignancy therapy.

Publications per year

1993–2017

Publications

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Esther Natalie Olíva, Caterina Alati, Valeria Santini et al. · The Lancet Haematology · 2017 · 162 citations · Full text

Medicine, Hematology, Pharmacotherapy +8

Differences among young adults, adults and elderly chronic myeloid leukemia patients

Fabio Castagnetti, Gabriele Gugliotta, Michele Baccarani et al. · Annals of Oncology · 2014 · 99 citations · Full text

Medicine, Geriatric Medicine, Oncology +10

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

Massimo Breccia, Fabio Efficace, Simona Sica et al. · Leukemia Research · 2015 · 64 citations

Pharmacy, Oncology, Pharmacotherapy +15

Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study

Roberto Latagliata, Dario Ferrero, Alessandra Iurlo et al. · Drugs & Aging · 2013 · 43 citations

Medicine, Hematology, Oncology +8

Multicentre phase III trial on fludarabine, cytarabine (Ara‐C), and idarubicin <i>versus</i> idarubicin, Ara‐C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

Domenico Russo, Michele Malagola, Antonio De Vivo et al. · British Journal of Haematology · 2005 · 42 citations · Full text

Medicine, Hematology, Oncology +17

1–5 of 17